US equities |
MU $1,044.84 ▼-3.97% NVDA $232.30 ▼-2.18% SNDK $1,598.58 ▼-5.54% AMD $622.23 ▼-3.66% INTC $106.98 ▼-5.43% SPCX $161.32 ▼-3.75% PLTR $197.97 ▲+1.98% META $715.00 ▼-0.87%
FinancialContent

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

65.08 -1.88 (-2.80%)
Delayed Quote Updated: 1:02 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial ↗
Vaxcyte (NASDAQ:PCVX) said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults.... 
Via MarketBeat
News headline image
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
From Vaxcyte, Inc.
Via GlobeNewswire
Keep an eye on the top gainers and losers in Monday's session. ↗
Via Chartmill
Monday's session: gap up and gap down stocks ↗
Via Chartmill
Discover the top movers in Monday's pre-market session. ↗
Via Chartmill
News headline image
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing ↗
Guggenhime surrendered shares to cover tax withholding on vesting RSUs, retaining about 164,000 shares valued at $10.12 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know ↗
Wassil exercised options at a steep discount and surrendered shares for tax withholding, maintaining a 0.1% ownership stake following the transactions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm ↗
The stock has surged 95% over the past year, and the CEO retains about 447,000 direct shares plus indirect holdings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Participate in Upcoming Investor Conferences
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Participate in Upcoming Investor Conferences
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment. 
Via The Motley Fool
News headline image
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
From Vaxcyte, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >